J&J JNJ stock has risen more than 6% in the past month. The reason behind the increase was a strong-than-expected ...

J&J’s Innovative Medicine unit is showing a growing trend. The segment’s sales rose 5.8% in 2024 on an organic basis. In 2025, J&J expects growth in the Innovative Medicine segment despite the ...

J&J’s Innovative Medicine unit is performing at above-market levels. Its growth is driven by existing products like Darzalex, Stelara, Tremfya, Uptraviand Erleada and the continued uptake of new ...

J&J's innovative medicine unit brought in fourth-quarter sales of $14.33 billion while its medtech unit generated $8.19 billion, up 4.4% and 6.7% respectively compared to a year ago. Sales of J&J ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them," noted Bill Martin, J&J Innovative Medicine's ...

Kevin Hamill, President, U.S. Immunology, Johnson & Johnson Innovative Medicine ... “As a company, J&J is committed to leading where medicine is going,” Hamill says.

global therapeutic area head of Neuroscience at Johnson & Johnson Innovative Medicine, said in a statement. Patients could experience improvements in their symptoms as early as 24 hours without ...

It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism ...

The PhRMA Foundation announced the appointment to its Board of Directors of Dr. John C. Reed, MD, PhD, Executive Vice President of Innovative Medicine R&D at Johnson & Johnson (J&J), and Dr. Donatello ...